New Therapy Update Aprocitentan: An Endothelin Receptor Antagonist for the Treatment of Drug-Resistant Systemic Hypertension.
Journal
Cardiology in review
ISSN: 1538-4683
Titre abrégé: Cardiol Rev
Pays: United States
ID NLM: 9304686
Informations de publication
Date de publication:
02 Aug 2023
02 Aug 2023
Historique:
medline:
2
8
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
aheadofprint
Résumé
Resistant hypertension (RH) is the state of uncontrolled blood pressure in the face of ostensibly optimal pharmacological intervention. It accounts for roughly one in six cases of hypertension, and is associated with more severe morbidity and mortality outcomes than is non-RH. The prevalence of RH implies a currently unmanaged pathology, which may involve the potent vasoconstrictor endothelin. Several endothelin receptor antagonists are currently marketed for pulmonary arterial hypertension, but none so far has been marketed for RH. Aprocitentan is currently in development, an endothelin receptor antagonist that effectively produces clinically significant and sustained decreases in systolic and diastolic blood pressure in the setting of RH.
Identifiants
pubmed: 37530539
doi: 10.1097/CRD.0000000000000591
pii: 00045415-990000000-00135
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to report.
Références
Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398:957–980.
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71:e127–e248.
Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635–1642.
Kumbhani DJ, Steg PG, Cannon CP, et al.; REACH Registry Investigators. Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis. Eur Heart J. 2013;34:1204–1214.
Muntner P, Davis BR, Cushman WC, et al.; ALLHAT Collaborative Research Group. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease. Hypertension. 2014;64:1012–1021.
Williams B, Mancia G, Spiering W, et al.; ESC Scientific Document Group. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;38:3021–3104.
Carey RM, Whelton PK; 2017 ACC/AHA Hypertension Guideline Writing Committee. Prevention, detection, evaluation, and management of high blood pressure in adults: synopsis of the 2017 American College of Cardiology/American Heart Association hypertension guideline. Ann Intern Med. 2018;168:351–358.
Buckallew AR, Tellor KB, Watson R, et al. Evaluation of the safety and tolerability of spironolactone in patients with heart failure and chronic kidney disease. Eur J Clin Pharmacol. 2021;77:955–960.
Frishman WH, Kaur S, Singh I, Tamirisa P. Endothelin as a Therapeutic Target in the Treatment of Cardiovascular Disease. In: Frishman WH, Sonnenblick EH, eds. Cardiovascular Pharmacotherapeutics, Second Edition. McGraw-Hill; 2003:527–543.
Donatelli M, Colletti I, Bucalo ML, et al. Plasma endothelin levels in NIDDM patients with macroangiopathy. Diabetes Res. 1994;25:159–164.
Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacol Rev. 2016;68:357–418.
Kohan DE, Rossi NF, Inscho EW, et al. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev. 2011;91:1–77.
Houde M, Desbiens L, D’Orléans-Juste P. Endothelin-1: biosynthesis, signaling and vasoreactivity. Adv Pharmacol. 2016;77:143–175.
Ge Y, Bagnall A, Stricklett PK, et al. Collecting duct-specific knockout of the endothelin B receptor causes hypertension and sodium retention. Am J Physiol Renal Physiol. 2006;291:F1274–F1280.
Löffler BM, Breu V, Clozel M. Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro 46-2005 on endothelin levels in rat plasma. FEBS Lett. 1993;333:108–110.
Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETBreceptors. J Appl Physiol. 1996;81:1510–1515.
Kirkby NS, Hadoke PWF, Bagnall AJ, et al. The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol. 2008;153:1105–1119.
Mathier MA, Ishizawar D. Bosentan. Expert Opin Pharmacother. 2010;11:1023–1034.
Krum H, Viskoper RJ, Lacourciere Y, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N Engl J Med. 1998;338:784–790.
Galiè N, Olschewski H, Oudiz RJ, et al.; Ambrisentan in Pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010–3019.
Chaumais MC, Guignabert C, Savale L, et al. Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2015;15:13–26.
Sidharta PN, Krähenbühl S, Dingemanse J. Pharmacokinetic and pharmacodynamic evaluation of macitentan, a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension. Expert Opin Drug Metab Toxicol. 2015;11:437–449.
Atsmon J, Dingemanse J, Shaikevich D, et al. Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects. Clin Pharmacokinet. 2013;52:685–692.
Weber MA, Black H, Bakris G, et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;374:1423–1431.
Roumen N, Egon P, Siegfried E. Darusentan: an effective endothelina receptor antagonist for treatment of hypertension. Am J Hypertens. 2002;15:583–589.
Black HR, Bakris GL, Weber MA, et al. Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens. 2007;9:760–769.
Bakris GL, Lindholm LH, Black HR, et al. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010;56:824–830.
Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther. 2008;327:736–745.
Fontes MSC, Dingemanse J, Halabi A, et al. Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment. Sci Rep. 2022;12:19067.
Sidharta PN, van Giersbergen PLM, Dingemanse J. Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects. J Clin Pharmacol. 2013;53:1131–1138.
Sidharta PN, Ulč I, Dingemanse J. Single-Dose pharmacokinetics and tolerability of aprocitentan, a dual endothelin receptor antagonist, in subjects with severe renal function impairment. Clin Drug Investig. 2019;39:1117–1123.
Fontes MSC, Dingemanse J, Sidharta PN. Multiple-dose pharmacokinetics, safety, and tolerability of aprocitentan, a dual endothelin receptor antagonist, in healthy Japanese and caucasian subjects. Clin Pharmacol Drug Dev. 2021;10:718–725.
Trensz F, Bortolamiol C, Kramberg M, et al. Pharmacological characterization of aprocitentan, a dual endothelin receptor antagonist, alone and in combination with blockers of the renin angiotensin system, in two models of experimental hypertension. J Pharmacol Exp Ther. 2019;368:462–473.
Sidharta PN, Fischer H, Dingemanse J. Absorption, distribution, metabolism, and excretion of aprocitentan, a dual endothelin receptor antagonist, in humans. Curr Drug Metab. 2021;22:399–410.
Verweij P, Danaietash P, Flamion B, et al. Randomized dose-response study of the new dual endothelin receptor antagonist aprocitentan in hypertension. Hypertension. 2020;75:956–965.
Desai M, Stockbridge N, Temple R. Blood pressure as an example of a biomarker that functions as a surrogate. AAPS J. 2006;8:E146–E152.
Schlaich MP, Bellet M, Weber MA, et al.; PRECISION investigators. Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial. Lancet. 2022;400:1927–1937.
Rahimi K, Bidel Z, Nazarzadeh M, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021;397:1625–1636.
Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351:543–551.
Makani H, Bangalore S, Desouza KA, et al. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ. 2013;346:f360.
Angeli F, Verdecchia P, Reboldi G. Aprocitentan, a dual endothelin receptor antagonist under development for the treatment of resistant hypertension. Cardiol Ther. 2021;10:397–406.
Abbas S, Ihle P, Harder S, et al. Risk of hyperkalemia and combined use of spironolactone and long-term ACE inhibitor/angiotensin receptor blocker therapy in heart failure using real-life data: a population- and insurance-based cohort. Pharmacoepidemiol Drug Saf. 2015;24:406–413.
Grosse SD. Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res. 2008;8:165–178.
Mason JM, Freemantle N, Gibson JM, et al.; SPLINT trial. Specialist nurse-led clinics to improve control of hypertension and hyperlipidemia in diabetes: economic analysis of the SPLINT trial. Diabetes Care. 2005;28:40–46.